Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma

被引:81
作者
Owen, C. [1 ,2 ]
Berinstein, N. L. [3 ,4 ]
Christofides, A. [5 ]
Sehn, L. H. [6 ,7 ]
机构
[1] Univ Calgary, Div Hematol & Hematol Malignancies, Calgary, AB, Canada
[2] Foothills Med Ctr, Calgary, AB, Canada
[3] Univ Toronto, Dept Med, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[5] IMPACT Medicom Inc, Toronto, ON, Canada
[6] Ctr Lymphoid Canc, BC Canc, Vancouver, BC, Canada
[7] Univ British Columbia, Vancouver, BC, Canada
关键词
Bruton tyrosine kinase inhibitors; mantle cell lymphoma; acalabrutinib; SINGLE-AGENT LENALIDOMIDE; TERM-FOLLOW-UP; PHASE-II; ACALABRUTINIB ACP-196; INVESTIGATORS CHOICE; UNITED-STATES; IBRUTINIB; MULTICENTER; BORTEZOMIB; ONO/GS-4059;
D O I
10.3747/co.26.4345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mantle cell lymphoma (MCL) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed or refractory (R/R) disease have a very poor prognosis. The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has proven to be an effective agent for patients with R/R MCL. Although usually well tolerated, ibrutinib can be associated with unique toxicities, requiring discontinuation in some patients. Effective and well-tolerated alternatives to ibrutinib for patients with R/R MCL are therefore needed. Novel BTK inhibitors such as acalabrutinib, zanubrutinib, and tirabrutinib are designed to improve on the safety and efficacy of first-generation BTK inhibitors such as ibrutinib. Data from single-arm clinical trials suggest that, compared with ibrutinib, second-generation BTK inhibitors have comparable efficacy and might have a more favourable toxicity profile. Those newer BTK inhibitors might therefore provide a viable treatment option for patients with R/R MCL.
引用
收藏
页码:E233 / E240
页数:8
相关论文
共 46 条
[1]  
Actavis Inc, 2016, ACT BORT PROD MON
[2]   Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].
Advani, Ranjana H. ;
Buggy, Joseph J. ;
Sharman, Jeff P. ;
Smith, Sonali M. ;
Boyd, Thomas E. ;
Grant, Barbara ;
Kolibaba, Kathryn S. ;
Furman, Richard R. ;
Rodriguez, Sara ;
Chang, Betty Y. ;
Sukbuntherng, Juthamas ;
Izumi, Raquel ;
Hamdy, Ahmed ;
Hedrick, Eric ;
Fowler, Nathan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94
[3]  
Alberta Health Services (ahs), 2018, CLIN PRACT GUID LYMP
[4]  
[Anonymous], BLOOD S1
[5]  
[Anonymous], 2015, BLOOD
[6]   Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile [J].
Barf, Tjeerd ;
Covey, Todd ;
Izumi, Raquel ;
van de Kar, Bas ;
Gulrajani, Michael ;
van Lith, Bart ;
van Hoek, Maaike ;
de Zwart, Edwin ;
Mittag, Diana ;
Demont, Dennis ;
Verkaik, Saskia ;
Krantz, Fanny ;
Pearson, Paul G. ;
Ulrich, Roger ;
Kaptein, Allard .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02) :240-252
[7]  
BC Cancer, 2013, LYMPHOMA
[8]   Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib (vol 1, pg 2610, 2017) [J].
Bye, A. P. ;
Unsworth, A. J. ;
Desborough, M. J. .
BLOOD ADVANCES, 2018, 2 (23) :3515-3515
[9]   Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].
Byrd, J. C. ;
Brown, J. R. ;
O'Brien, S. ;
Barrientos, J. C. ;
Kay, N. E. ;
Reddy, N. M. ;
Coutre, S. ;
Tam, C. S. ;
Mulligan, S. P. ;
Jaeger, U. ;
Devereux, S. ;
Barr, P. M. ;
Furman, R. R. ;
Kipps, T. J. ;
Cymbalista, F. ;
Pocock, C. ;
Thornton, P. ;
Caligaris-Cappio, F. ;
Robak, T. ;
Delgado, J. ;
Schuster, S. J. ;
Montillo, M. ;
Schuh, A. ;
de Vos, S. ;
Gill, D. ;
Bloor, A. ;
Dearden, C. ;
Moreno, C. ;
Jones, J. J. ;
Chu, A. D. ;
Fardis, M. ;
McGreivy, J. ;
Clow, F. ;
James, D. F. ;
Hillmen, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223
[10]   Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].
Byrd, John C. ;
Harrington, Bonnie ;
O'Brien, Susan ;
Jones, Jeffrey A. ;
Schuh, Anna ;
Devereux, Steve ;
Chaves, Jorge ;
Wierda, William G. ;
Awan, Farrukh T. ;
Brown, Jennifer R. ;
Hillmen, Peter ;
Stephens, Deborah M. ;
Ghia, Paolo ;
Barrientos, Jacqueline C. ;
Pagel, John M. ;
Woyach, Jennifer ;
Johnson, Dave ;
Huang, Jane ;
Wang, Xiaolin ;
Kaptein, Allard ;
Lannutti, Brian J. ;
Covey, Todd ;
Fardis, Maria ;
McGreivy, Jesse ;
Hamdy, Ahmed ;
Rothbaum, Wayne ;
Izumi, Raquel ;
Diacovo, Thomas G. ;
Johnson, Amy J. ;
Furman, Richard R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332